

CORRECTION

# Correction: Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer

**Shingo Hatakeyama, Takuya Koie, Takuma Narita, Shogo Hosogoe, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama**

The words “Risk Factors for” appear twice in the title of this article. The correct title is: Renal Function Outcomes and Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. The correct citation is: Hatakeyama S, Koie T, Narita T, Hosogoe S, Yamamoto H, Tobisawa Y, et al. (2016) Renal Function Outcomes and Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. PLoS ONE 11(2): e0149544. doi:[10.1371/journal.pone.0149544](https://doi.org/10.1371/journal.pone.0149544)

There are formatting errors in [Table 1](#) and [Table 3](#) of the published article. Please see the correct [Table 1](#) and [Table 3](#) here.



## OPEN ACCESS

**Citation:** Hatakeyama S, Koie T, Narita T, Hosogoe S, Yamamoto H, Tobisawa Y, et al. (2016) Correction: Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. PLoS ONE 11(3): e0151742. doi:[10.1371/journal.pone.0151742](https://doi.org/10.1371/journal.pone.0151742)

**Published:** March 15, 2016

**Copyright:** © 2016 Hatakeyama et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Table 1. Clinical and pathological patient characteristics.**

	All patients			Matched patients		
	Incontinent	Continent	<i>P value</i>	Incontinent	Continent	<i>P value</i>
n	47	68		34	34	
Ileal conduit / cutaneous ureterostomy, n =	17 / 30			14 / 20		
Median age*, years (IQR)	67 (64–76)	68 (58–71)	0.018	66 (61–72)	68 (58–71)	0.437
Gender* (M/F), n =	39 / 8	47 / 21	0.126	26 / 8	27 / 7	0.770
Mean ECOG-PS* (±SD)	0.0±0.2	0.0±0.0	0.160	0.1±0.2	0.0±0.0	0.156
Median follow-up, months (IQR)	72 (53–112)	97 (70–125)	0.093	73 (54–98)	101 (74–126)	0.139
Neoadjuvant chemotherapy, n =	18 (38%)	35 (51%)	0.186	13 (38%)	16 (47%)	0.624
TNM classification						
cT* (±SD)	2.4±0.9	2.3±0.8	0.259	2.4±0.9	2.2±0.8	0.212
pT (±SD)	2.1±1.2	1.4±1.2	0.001	2.0±1.2	1.3±1.1	0.009
pN+, n =	7 (15%)	1 (1.5%)	0.008	6 (18%)	1 (3%)	0.105
Cardiovascular disease*, n =	3 (6%)	9 (13%)	0.354	2 (6%)	1 (3%)	0.555
Hypertension*, n =	21 (45%)	27 (40%)	0.701	14 (41%)	14 (41%)	1.000
Diabetes*, n =	5 (11%)	8 (12%)	1.000	5 (15%)	6 (18%)	0.742
Median blood loss, kg (IQR)	1.5 (0.9–2.3)	1.3 (0.9–2.0)	0.131	1.4 (1.1–1.9)	1.3 (0.9–1.6)	0.153
Median operative duration, hours (IQR)	4.7 (4.0–6.3)	5.0 (4.4–6.2)	0.897	4.8 (4.0–6.2)	4.8 (4.5–6.0)	0.789
Postoperative Complications, n =	18 (38%)	26 (38%)	1.000	19 (56%)	19 (56%)	1.000
Postoperative hydronephrosis (> G1), n =	16 (34%)	5 (7%)	<0.001	12 (35%)	4 (12%)	0.043
Ureteral stent, n =	23 (49%)	0 (0%)	<0.001	15 (44%)	0 (0%)	<0.001
Ileal conduit, stent (+)	2 (12%)			1 (7%)		
Cutaneous ureterostomy, stent (+)	21 (70%)			14 (70%)		
Recurrence, n =	15 (32%)	6 (9%)	0.003	10 (29%)	2 (6%)	0.023
Chemotherapy for recurrent disease, n =	14 (30%)	4 (6%)	0.001	9 (27%)	1 (2.9%)	<0.001
Median cycle (IQR)	4 (2–6)	4 (1–5)	0.413	6 (3–14)	3 (1–4)	0.029

\* applied for propensity score-matching SD, standard deviation; IQC, interquartile range.

doi:10.1371/journal.pone.0151742.t001

**Table 3. Multivariate Cox regression analyses of risk factors for postoperative stage 3B CKD (eGFR < 45 mL/min/1.73 m<sup>2</sup>).** Incontinent urinary diversion was divided into 2 groups, and compared with orthotopic ileal neobladder in the model 2. Comorbidities included past history of CVD, HTN, or DM.

Variables (Model 1)	Risk factors	P value	HR	95%CI
Age	Older than 67 years	0.043	2.90	1.03–8.13
Comorbidities	Pre-existing	0.110	2.40	0.82–7.02
eGFR before surgery	< 60 ml/min/1.73m <sup>2</sup>	0.020	3.25	1.20–8.80
Stent indwelling	Positive	0.163	0.40	0.11–1.45
Postoperative hydronephrosis	Greater than grade 1	0.002	5.15	1.81–14.6
Tumor recurrence	Positive	0.900	0.91	0.22–3.71
Chemotherapy for recurrent disease	Positive	0.290	0.43	0.09–2.04
Urinary diversion	Incontinent diversion	0.016	4.41	1.33–14.7
<b>Variables (Model 2)</b>				
Age	Older than 67 years	0.025	3.47	1.17–10.4
Comorbidities	Pre-existing	0.129	2.32	0.78–6.87
eGFR before surgery	< 60 ml/min/1.73m <sup>2</sup>	0.016	3.32	1.25–8.82
Stent indwelling	Positive	0.065	0.22	0.04–1.10
Postoperative hydronephrosis	Greater than grade 1	0.003	4.81	1.70–13.7
Tumor recurrence	Positive	0.969	0.97	0.23–4.11
Chemotherapy for recurrent disease	Positive	0.196	0.33	0.06–1.77
Urinary diversion (ref. neobladder)	Cutaneous ureterostomy	0.012	8.92	1.63–48.7
	Ileal conduit	0.069	3.44	0.91–13.1

doi:10.1371/journal.pone.0151742.t002

## Reference

1. Hatakeyama S, Koie T, Narita T, Hosogoe S, Yamamoto H, Tobisawa Y, et al. (2016) Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. PLoS ONE 11(2): e0149544. doi:[10.1371/journal.pone.0149544](https://doi.org/10.1371/journal.pone.0149544) PMID: [26901860](https://pubmed.ncbi.nlm.nih.gov/26901860/)